Editorial: Diet-microbe-host interactions in metabolic syndrome

Editorial on the Research Topic
Diet-microbe-host interactions in metabolic syndrome

Affecting around 25% of the world's adult population, metabolic syndrome (MetS) is a cluster of metabolic disorders such as insulin resistance, dysglycemia, dyslipidemia, hypertension and central adiposity with visceral fat accumulation (1, 2). Given its impact on host immunity and metabolism, the gut microbiome is a possible culprit in triggering MetS (3, 4). The scope of the “Diet-microbe-host interactions in metabolic syndrome” Research Topic was to report new findings in the field of MetS including microbiota patterns linked to metabolic disease, effects of dietary/probiotic/pre-biotic/post-biotic interventions on MetS complications and inflammatory status, host-microbe interactions in metabolic disease, clinical trials using microbiota targeting, as well as personalized medicine approaches.

In this special e-collection there are 11 papers covering several of the above-mentioned aspects.

Reports of gut dysbiosis associated with Western diet consumption have led to increased interest in the role of the microbiome in the development of obesity and MetS (5). To better study these aspects, it is crucial to develop research models that accurately reflect MetS affected populations. Chehade et al. have formulated a modified Standard American Diet (mSAD) to induce the physiological parameters associated with MetS in mice (A modified standard American diet induces physiological parameters associated with metabolic syndrome in C57BL/6J mice). The mSAD administration was associated with altered glucose metabolism, increased body weight and reduced abundance of the Akkermansia genus.

Chronic systemic inflammation had long been considered as a major player in the development and progression of non-communicable diseases such as MetS (6). Pro-inflammatory cytokines, other adipokines, along free fatty acids secreted from adipose tissue may activate and/or accelerate the development of insulin resistance and other pathological effects. Dietary manipulations may improve the inflammatory status and the microbiota profile in obesity. A study performed on C57BL/6 mice studied the effects of habitual consumption of the traditional peanut cultivar, HN, and the new high-oleic peanut cultivar, HO, as an integral part of diet-induced obesity (Metabolic and microbiome alterations following the enrichment of a high-fat diet with high oleic acid peanuts versus the traditional peanuts cultivar in mice) (Anavi-Cohen et al.). The new high oleic acid cultivar was metabolically superior to the traditional peanut type and was associated with a better inflammatory state and microbiome signature (lower levels of the Erysipelotrichaceae family).

In mice, acidic activated charcoal improved high fat die-induced obesity and insulin resistance in a dose-dependent manner without any serious adverse effects. Metabolomic analysis of cecal contents revealed that cholesterol, neutral lipids, and bile acids were excreted at significantly higher levels in the feces of mice under charcoal treatment (Acidic activated charcoal prevents obesity and insulin resistance in high-fat diet-fed mice) (Zhang et al.).

Using an animal model for non-alcoholic fatty liver disease (NAFLD), Jian et al. showed that long-term exposure to excessive dietary valine influenced amino acid and fatty acid metabolism by promoting fatty acid synthesis, impairing amino acid metabolism, and inducing amino acid imbalance (Amino acid and fatty acid metabolism disorders trigger oxidative stress and inflammatory response in excessive dietary valine-induced NAFLD of laying hens).

Another nutritional supplement, represented by astaxanthin (ATX), a xanthophyll carotenoid, was reported to prevent steatohepatitis and hepatic oxidative stress in mice with diet-induced obesity (Astaxanthin from Haematococcus pluvialis prevents high-fat diet-induced hepatic steatosis and oxidative stress in mice by gut-liver axis modulating properties) (Wang, Xu et al.). ATX exerted important effects on the microbiome by significantly inhibiting the growth of obesity-related genera Parabacteroides and Desulfovibrio while promoting the growth of Akkermansia and Allobaculum genera.

Polydatin (POD), a natural precursor and glycosylated form of resveratrol had important effects on the microbiome by increasing the abundance of beneficial bacterial genera (Butyrycimonas, Bifidobacterium). POD administration altered the glucolipid dysmetabolism, insulin resistance, and non-alcoholic fatty liver disease by reducing the oxidative stress and preventing AMP-activated protein kinase (AMPK) suppression induced by high-fructose diet in mice (Polydatin, a glycoside of resveratrol, is better than resveratrol in alleviating non-alcoholic fatty liver disease in mice fed a high-fructose diet) (Zhao et al.).

Treatment with the polyphenol rich Black chokeberry (BCP) reduced body weight, liver, and white adipose tissue weight and alleviated hepatic steatosis and dyslipidemia in rats with obesity [Modulation of the gut microbiota and lipidomic profiles by black chokeberry (Aronia melanocarpa L.) polyphenols via the glycerophospholipid metabolism signaling pathway] (Zhu et al.). BCPs supplementation increased the relative abundance of genera such as Bacteroides, Romboutsia, Prevotella, and Akkermansia and decreased the relative abundance of genera Clostridium and Desulfovibrio.

Short-chain fatty acids (SCFA) such as acetate, propionate and butyrate are produced by bacterial fermentation of non-digestible carbohydrates. HFD (high fat diet) before and during pregnancy significantly induced obesity and worsen glucose tolerance, lipid metabolism and insulin sensitivity in gestational mice. Ding et al. emphasized the importance of the rhythmicity of gut microbiota-derived SCFAs in mediating circadian disruption in response to the HFD in gestational mice (A high-fat diet disrupts the hepatic and adipose circadian rhythms and modulates the diurnal rhythm of gut microbiota-derived short-chain fatty acids in gestational mice).

In human studies, anti-inflammatory agents together with dietary interventions may be therapeutically useful in treating and preventing MetS (7, 8). A meta-analysis performed by Wang, Liu et al. (Effects of dietary intervention on inflammatory markers in metabolic syndrome: A systematic review and meta-analysis) provided evidence that dietary intervention could improve immunological properties, particularly IL-6, in MetS. Subsequent analysis based on subgroups indicated that these results were affected by dietary patterns in MetS. Despite this, it did not reveal the association between dietary intervention and the IL-1β, CRP, and TNF-α levels. Nevertheless, more research is needed to underpin the mechanisms underlying the effect of dietary intervention on MetS associated inflammatory markers.

In women with obesity, a low-glycemic diet significantly altered the microbiota by lowering the abundance of Gemmiger formicilis, Collinsella aerofaciens, and Escherichia coli (Beneficial effects of a low-glycemic diet on serum metabolites and gut microbiota in obese women with Prevotella and Bacteriodes enterotypes: A randomized clinical trial) (Hur et al.). Importantly, the low glycemic diet was more efficient in women with obesity and a Prevotella dominant enterotype suggesting that dietary patterns could impact metabolic traits differently in different enterotypes, indicating the need of a personalized diet based on enterotypes. Further studies are needed to find appropriate diets for each enterotype.

The use of microbiome regulation (especially the enrichment of some SCFA-producing bacteria or the targeting of specific SCFA-producing bacteria, such as the representative A. muciniphila strain, to improve the intestinal environment to help adults with obesity lose weight) has become an attractive strategy reported in several clinical studies (The therapeutic effect of SCFA-mediated regulation of the intestinal environment on obesity) (You et al.). Nevertheless, the microbiota is a complex ecosystem, and whether SCFA play a role directly or by regulating gut microbes remains to be explored.

Dietary interventions are essential tools for modifying the microbiota and improve host health. Future studies characterizing the effects of dietary components through the host-microbe axis are pivotal to provide evidence-based dietary interventions to prevent and ameliorate MetS and other metabolic disorders.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

GG: draft preparation. AP, MR, and MC: review and editing. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by UEFISCDI (project ID PN-III-P1-1.1-PD-2019-0499, grant numbers 224/2021, C1.2.PFE-CDI.2021-587, CNFIS-FDI-2022-0675, and AOSR Teams 288/20.02.2022).

Acknowledgments

The research project PD224/2021 (PD-2019-0499) is gratefully acknowledged.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Giglio RV, Stoian AP, Patti AM, Rizvi AA, Sukhorukov V, Ciaccio M, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of metabolic syndrome. Curr Pharm Des. (2021) 27:3729–40. doi: 10.2174/1381612827666210412145915

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Rizvi AA, Stoian AP, Rizzo M. Metabolic syndrome: from molecular mechanisms to novel therapies. Int J Mol Sci. (2021) 22:10038. doi: 10.3390/ijms221810038

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Cătoi AF, Vodnar DC, Corina A, Nikolic D, Citarrella R, Pérez-Martínez P, et al. Gut microbiota, obesity and bariatric surgery: current knowledge and future perspectives. Curr Pharm Des. (2019) 25:2038–50. doi: 10.2174/1381612825666190708190437

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Cătoi AF, Corina A, Katsiki N, Vodnar DC, Andreicuţ AD, Stoian AP, et al. Gut microbiota and aging-a focus on centenarians. Biochim Biophys Acta Mol Basis Dis. (2020) 1866:165765. doi: 10.1016/j.bbadis.2020.165765

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Hintze KJ, Benninghoff AD, Cho CE, Ward RE. Modeling the western diet for preclinical investigations. Adv Nutr. (2018) 9:263–71. doi: 10.1093/advances/nmy002

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. (2011) 121:2111–7. doi: 10.1172/JCI57132

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Giglio RV, Carruba G, Cicero AFG, Banach M, Patti AM, Nikolic D, et al. Pasta supplemented with opuntia ficus-indica extract improves metabolic parameters and reduces atherogenic small dense low-density lipoproteins in patients with risk factors for the metabolic syndrome: a four-week intervention study. Metabolites. (2020) 10:428. doi: 10.3390/metabo10110428

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Patti AM, Carruba G, Cicero AFG, Banach M, Nikolic D, Giglio RV, et al. Daily use of extra virgin olive oil with high oleocanthal concentration reduced body weight, waist circumference, alanine transaminase, inflammatory cytokines and hepatic steatosis in subjects with the metabolic syndrome: a 2-month intervention study. Metabolites. (2020) 10:392. doi: 10.3390/metabo10100392

PubMed Abstract | CrossRef Full Text | Google Scholar